Avid Bioservices Inc (CDMO)

[cjgaddy]

BETABODIES Patent: U.S./Granted=2-17-15; EUR./INTENT-TO-GRANT=11-8-15. Excellent find, Endo!

BETABODIES (ex: KL15), “potentially the next generation of PS-targeting cancer therapeutics” - generated by fusing domains of the PS-binding the plasma protein, B2-glycoprotein I (B2GPI), to the Fc region of mouse IgG2a. Such ‘betabodies’ potentially have the following advantages: they bind directly to PS and do not require a cofactor protein (B2GPI) for binding; they can be made fully human; they are smaller in size (100 vs. 250 KDa); and they have slower blood clearance rates (half-life of ~5days vs. Bavi’s ~1day).
…See 7-6-13, “Entdoc, here’s a bunch of stuff on Betabodies” http://investorshub.advfn.com/boards/read_msg.aspx?message_id=89680206http://tinyurl.com/khopa3d

- - - - - - - - - - - - - - - -U.S. Patent #8,956,616:
UTSW/PPHM’s BetaBodies patent AWARDED(GRANTED) 2-17-15, U.S. Patent #8,956,616
‘BETABODIES’ patent app #20060228299, filed 1-24-2006, pub 10-12-2006, AWARDED 2-17-2015…
"Constructs Binding to Phosphatidylserine and Their Use in Disease Treatment" ("Betabodies & Receptorbodies”)
Inventors: Philip E. Thorpe, Troy A. Luster, Steven W. King
Assignee1: BOARD OF REGENTS, UNIV. OF TEXAS SYSTEM, 201 W. 7TH ST, AUSTIN, TX
Assignee2: PEREGRINE PHARMACEUTICALS, INC., 14272 FRANKLIN AVE, TUSTIN, CA
USPTO Patent #8,956,616: http://tinyurl.com/nj4jpry (Granted 2-17-15)
ABSTRACT: “Disclosed are new phosphatidylserine binding constructs with surprising combinations of properties, and a range of diagnostic and therapeutic conjugates thereof. The new constructs effectively bind phosphatidylserine targets in disease and enhance their destruction, and can also specifically deliver attached imaging or therapeutic agents to the disease site. Also disclosed are methods of using the new construct compositions, therapeutic conjugates and combinations thereof in tumor vasculature targeting, cancer diagnosis and treatment, and for treating viral infections and other diseases.”
1. A construct comprising an antibody Fc region operatively attached to two .beta.2-glycoprotein I (.beta.2GPI) polypeptides, wherein said .beta.2GPI polypeptides each comprise at least an intact domain V of .beta.2GPI, wherein said intact domain V binds to phosphatidylserine, wherein said .beta.2GPI polypeptides form a dimer when attached to said antibody Fc region and wherein said construct retains the property of binding to phosphatidylserine.
[0015] ReceptorBodies & BetaBodies: The invention first provides a range of phosphatidylserine binding construct compositions, in which the constructs comprise at least a first phosphatidylserine binding protein, polypeptide or receptor operatively attached to at least a first antibody Fc region. Joining a phosphatidylserine binding protein, polypeptide or "receptor" to an "antibody" Fc region gives rise to the terms "receptorbody" and "receptorbodies", which are used herein to refer to the phosphatidylserine-binding Fc constructs of the invention.
- - - - - - - - - - - - - - - -EUROPE Patent #EP06719706:
[Corresponding EUR. PATENT: https://register.epo.org/application?lng=en&number=EP06719706
11-8-15/Eur.: “Communication of intention to grant the patent.”]

= = = = = = = = = = = = = = = = = = = = = = = = =
• Betabodies (Clipped/Nicked B2GPI - ex: KL15, “2nd-gen. PS-Targeting”) - bind to PS directly, are smaller in size (100 vs. 250KDa) and have a longer serum half-life (~5days) than natural antibodies (Bavi=~1day) – see 7-6-13, “Entdoc, here’s a bunch of stuff on Betabodies:” http://investorshub.advfn.com/boards/read_msg.aspx?message_id=89680206

11-6-14 Edcpf/iHub#196158, “Such Betabodies potentially have advantages over bavituximab”: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=107891618

From Peregrine’s IASCL’15 9-8-15 PR: http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=930479
”Peregrine's PS signaling pathway inhibitor candidates, including bavituximab, reverse the immunosuppressive environment that many tumors establish in order to proliferate, while also fighting cancer by activating macrophages and cytotoxic T cells in tumors.”